Arbutus Biopharma Corp (NASDAQ:ABUS)
| Market Cap | $775.58M-19.1% |
| Revenue (ttm) | $181.49M+1142.6% |
| Net Income | $219.91M+620.2% |
| EPS | $1.12+599.3% |
| Shares Out | 198.11M |
| PE Ratio | 3.46 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,096,496.477 |
| Open | $3.86 |
| Previous Close | $3.88 |
| Day's Range | $3.81 - $3.92 |
| 52-Week Range | $3.50 - $5.45 |
| Beta | 0.62 |
| Analysts | Buy |
| Price Target | $8.50(+117.11%) |
| Earnings Date | Mar 4, 2027 |
About ABUS
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Next catalysts
- Mar 4, 2027Earnings report
$ABUS stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in ABUS holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ABUS's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ABUS Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New ABUS patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ABUS from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ABUS
| VTIVanguard Morningstar Total Stock Market ETF | $24.07M |
| IWMiShares Russell 2000 ETF | $15.69M |
| XBIState Street SPDR S&P Biotech ETF | $11.44M |
| VXFVanguard Extended Market ETF | $8.55M |
| IWOiShares Russell 2000 Growth ETF | $5.93M |
| IBBiShares Biotechnology ETF | $4.77M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from ABUS’s recent data — informational, not investment advice
What’s Behind the Score
News check: Arbutus reported Q3 2026 results with corporate updates; coverage is factual and neutral without evident negative catalysts.